

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/168420 A1

(51) International Patent Classification:

A61K 31/18 (2006.01) A61K 45/06 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/063701

(22) International Filing Date:

03 March 2023 (03.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/268,897 04 March 2022 (04.03.2022) US

(71) Applicant: TVARDI THERAPEUTICS, INC. [US/US];
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land,
Texas 77478 (US).

(72) Inventors: ALIBHAI, Imran; 3 Sugar Creek Center
Boulevard, Suite 525, Sugar Land, Texas 77478 (US). DE
ACHAVAL, Sofia; 3 Sugar Creek Center Boulevard, Suite
525, Sugar Land, Texas 77478 (US). GYURIS, Jenő; 3 Sug-
ar Creek Center Boulevard, Suite 525, Sugar Land, Texas
77478 (US).

(74) Agent: CHOI, Boyeon et al.; 100 Northern Avenue,
IP DOCKETING DEPT./7TH FL, Boston, Massachusetts
02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER




FIG. 1

(57) Abstract: Provided herein are methods of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a STAT inhibitor and an effective amount of an immune checkpoint inhibitor (e.g., PD-1 inhibitor or PD-L1 inhibitor).

WO 2023/168420 A1